- Home
- YCBD vs BJDX Comparison
YCBD vs BJDX Comparison
Compare YCBD & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YCBD
- BJDX
- Stock Information
- Founded
- YCBD 2015
- BJDX 2015
- Country
- YCBD United States
- BJDX United States
- Employees
- YCBD N/A
- BJDX N/A
- Industry
- YCBD Biotechnology: Pharmaceutical Preparations
- BJDX Medical Specialities
- Sector
- YCBD Health Care
- BJDX Health Care
- Exchange
- YCBD Nasdaq
- BJDX Nasdaq
- Market Cap
- YCBD 1.9M
- BJDX 1.8M
- IPO Year
- YCBD N/A
- BJDX 2021
- Fundamental
- Price
- YCBD $0.46
- BJDX $3.64
- Analyst Decision
- YCBD
- BJDX
- Analyst Count
- YCBD 0
- BJDX 0
- Target Price
- YCBD N/A
- BJDX N/A
- AVG Volume (30 Days)
- YCBD 193.9K
- BJDX 48.0M
- Earning Date
- YCBD 12-20-2024
- BJDX 11-07-2024
- Dividend Yield
- YCBD N/A
- BJDX N/A
- EPS Growth
- YCBD N/A
- BJDX N/A
- EPS
- YCBD N/A
- BJDX N/A
- Revenue
- YCBD $20,636,546.00
- BJDX N/A
- Revenue This Year
- YCBD N/A
- BJDX N/A
- Revenue Next Year
- YCBD $9.38
- BJDX N/A
- P/E Ratio
- YCBD N/A
- BJDX N/A
- Revenue Growth
- YCBD N/A
- BJDX N/A
- 52 Week Low
- YCBD $0.42
- BJDX $0.07
- 52 Week High
- YCBD $1.73
- BJDX $31.28
- Technical
- Relative Strength Index (RSI)
- YCBD 46.39
- BJDX 97.41
- Support Level
- YCBD $0.42
- BJDX $0.07
- Resistance Level
- YCBD $0.52
- BJDX $0.14
- Average True Range (ATR)
- YCBD 0.05
- BJDX 0.06
- MACD
- YCBD -0.00
- BJDX 0.23
- Stochastic Oscillator
- YCBD 29.63
- BJDX 100.00
About YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD and hempMD. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD bath bombs, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.